Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients

Wang,Lina; Wang,Hua-Cheng; Chen,Cha; Zeng,Jianming; Wang,Qian; Zheng,Lei; Yu,Huan-Du

doi:10.3892/etm.2013.937

Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients

Authors:
- Lina Wang
- Hua-Cheng Wang
- Cha Chen
- Jianming Zeng
- Qian Wang
- Lei Zheng
- Huan-Du Yu
View Affiliations

Affiliations: Department of Laboratory Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510006, P.R. China, Department of Laboratory Medicine, Guangzhou Brain Hospital, Guangzhou 510370, P.R. China, Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China, Department of Laboratory Medicine, Kingmed Diagnostics, Guangzhou 510006, P.R. China
Published online on: January 30, 2013 https://doi.org/10.3892/etm.2013.937
Pages: 1101-1104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sepsis is a subtype of systemic inflammatory response syndrome (SIRS), which is characterized by infection. Circulating microRNAs (miRNAs), including miR-150, miR-146a and miR-223, are potential biomarkers of sepsis. In this study, we demonstrated that measuring the relative expression of miR-146a/U6 in plasma, using the 2-∆∆Ct method, provides a method for differentiating between sepsis and non-sepsis-SIRS. We observed a significant increase in miR-146a expression in the initial cohort of 6 non-sepsis-SIRS patients compared to the 4 sepsis patients (P=0.01) and in the second cohort of 8 non-sepsis-SIRS patients compared to the 10 sepsis patients (P=0.027). Additionally, we identified that sodium citrate and ethylenediaminetetraacetic acid (EDTA) K2 may be used as anticoagulant reagents. Generation of a standard curve is not necessary in these diagnostic tests, unless the standard of normalization is carefully selected. Thus we provide more detailed guidance for the clinical use of circulating miRNA biomarkers.

View Figures

View References

1	Simon L, Gauvin F, Amre DK, Saint-Louis P and Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 39:206–217. 2004. View Article : Google Scholar : PubMed/NCBI
2	Tang BM, Eslick GD, Craig JC and McLean AS: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 7:210–217. 2007. View Article : Google Scholar : PubMed/NCBI
3	Young L: Gram-negative sepsis. Principles and Practice of Infectious Diseases. Mandell GL, Douglas RG and Bennett JE: Churchill Livingstone; New York: pp. 611–636. 1990
4	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
5	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
6	McDonald JS, Milosevic D, Reddi HV, Grebe SK and Algeciras-Schimnich A: Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 57:833–840. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ho AS, Huang X, Cao H, et al: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 3:109–113. 2010. View Article : Google Scholar : PubMed/NCBI
8	Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hou J, Wang P, Lin L, et al: MicroRNA-146a feedback inhibits RIGI-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1 and IRAK2. J Immunol. 183:2150–2158. 2009. View Article : Google Scholar : PubMed/NCBI
10	Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
11	Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, Wan XJ and Zhu KM: Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun. 394:184–188. 2010. View Article : Google Scholar : PubMed/NCBI
12	Bone RC, Balk RA, Cerra FC, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 101:1644–1655. 1992. View Article : Google Scholar
13	Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 31:1250–1256. 2003. View Article : Google Scholar : PubMed/NCBI
14	No authors listed. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 20:864–74. 1992. View Article : Google Scholar
15	Dellinger RP, Levy MM, Carlet JM, et al: Surviving sepsis sampaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 36:296–327. 2008. View Article : Google Scholar
16	Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E and Bates DW: Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. Critical Care Medicine. 31:670–675. 2003. View Article : Google Scholar : PubMed/NCBI
17	Takeuchi O, Hoshino K, Kawai T, et al: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity. 11:443–451. 1999. View Article : Google Scholar : PubMed/NCBI
18	Vasilescu C, Rossi S, Shimizu M, et al: MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One. 4:e74052009. View Article : Google Scholar : PubMed/NCBI
19	Nahid MA, Pauley KM, Satoh M, et al: miR-146a is critical for endotoxin-induced tolerance, implication in innate immunity. J Biol Chem. 284:34590–34599. 2009. View Article : Google Scholar : PubMed/NCBI
20	Formisano-Treziny C, de San Feliciano M and Gabert J: Development of plasmid calibrators for absolute quantification of miRNAs by using real-time qPCR. J Mol Diagn. 14:314–321. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hromadnikova I, Kotlabova K, Doucha J, Dlouha K and Krofta L: Absolute and relative quantification of placenta-specific micrornas in maternal circulation with placental insufficiency-related complications. J Mol Diagn. 14:160–167. 2012. View Article : Google Scholar
22	Pu XX, Huang GL, Guo HQ, et al: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 25:1674–1680. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tomasetti M, Staffolani S, Nocchi L, et al: Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 45:575–581. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Jia Y, Zheng R, et al: Plasma microRNA-122 as a biomarker fro viral-, alcohol- and chemical-related hepatic diseases. Clin Chem. 56:1830–1838. 2010. View Article : Google Scholar : PubMed/NCBI
25	Starkey Lewis PJ, Dear J, Platt V, et al: Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 54:1767–1776. 2011.PubMed/NCBI
26	Gui J, Tian Y, Wen X, et al: Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 120:183–193. 2011. View Article : Google Scholar : PubMed/NCBI